| Gerald Heinz Möller |
Dr. Gerald Heinz Möller is a Member-Supervisory Board at AdrenoMed AG, a Chairman-Supervisory Board at 4sigma (Bermuda) Ltd., a Chairman-Supervisory Board at MorphoSys AG, a Chairman-Supervisory Board at AYOXXA Biosystems GmbH and an Executive Chairman at Pelikan Technologies, Inc. He is on the Board of Directors at AdrenoMed AG. Dr. Möller was previously employed as a Vice Chairman-Supervisory Board by Genticel SA, an Independent Director by Illumina, Inc., a Head-Development & Strategic Marketing by Roche Holding AG, a Chief Executive Officer by Boehringer Mannheim Group, a Chief Technology Officer by Corange Ltd., a President by Boehringer Mannheim Corp., a Director-Scientific Department by Boehringer Mannheim Yamanaouchi KK, a Non-Executive Chairman by B·R·A·H·M·S AG, a Chairman-Supervisory Board by BioAgency AG, a Chief Executive Officer by Boehringer Ingelheim GmbH, a President-Advanced Diagnostics & Biochemicals by Boehringer Mannheim, a Chairman by DefaqtoMedia Ltd., a Chairman-Supervisory Board by Definiens AG, a Member-Supervisory Board by febit holding GmbH, a Non-Executive Director by Ferraris Group Plc, a Chairman by Foundation for Innovative New Diagnostics, an Investment Adviser by HBM Partners AG, a Head-Global Development & Strategic Marketing by Hoffmann-La Roche, Inc., and a Chairman-Supervisory Board by mtm laboratories AG. He also served on the board at Bionostics, Inc. and Vivacta Ltd. He received his doctorate degree from the University of Kiel. |
| Tim Demuth |
Tim Demuth is currently the Chief Research & Development Officer at MorphoSys AG since 2022. Prior to this, he was the Chief Medical Officer & Senior Vice President at Pieris Pharmaceuticals, Inc. from 2021 to 2022. He also held positions as VP & Head-Global Clinical Development Oncology at Merck KGaA and Head-Clinical Development at Sandoz AG. Dr. Demuth obtained a doctorate degree from The Johannes Gutenberg University of Mainz. |
| Luisa Ciccarelli |
Luisa Ciccarelli is currently the Senior VP & Global Head-Technical Operations at MorphoSys AG. She previously worked as the Head-Production at Novartis Austria GmbH. She is a graduate of Università degli Studi di Napoli Federico II. |
| Arkadius Pichota |
Arkadius Pichota is currently the Chief Executive Officer at MorphoSys AG since 2024. Prior to this, he served as the President & General Manager at Navigate BioPharma Services, Inc. |
| Charlotte Lohmann |
Ms. Charlotte Lohmann is a Chief Legal & Human Resources Officer at MorphoSys AG and an Independent Non-Executive Director at Vivoryon Therapeutics NV. She is on the Board of Directors at Vivoryon Therapeutics NV. Ms. Lohmann was previously employed as a Senior VP-Legal Affairs & Human Resources by WILEX AG. She received her graduate degree from Ludwig-Maximilians-Universität München. |
| Barbara Krebs-Pohl |
Barbara Krebs-Pohl is currently the Director at Human Immunology Biosciences, Inc. and the Chief Business Officer at MorphoSys AG. Previously, she worked as the Director at HIBio, Inc. Dr. Krebs-Pohl holds a graduate degree from Universität zu Köln and a doctorate degree from The Johannes Gutenberg University of Mainz. |
| Günter Wellnhofer |
Günter Wellnhofer has a current job as the Head-Facilities at MorphoSys AG since 2020. |
| Lukas Gilgen |
Lukas Gilgen is currently working as the Chief Financial Officer at MorphoSys AG since 2024. Prior to this, he worked at Novartis International AG as the Lead-Transaction & Enterprise Projects. |
| Daniel Palmacci |
Daniel Palmacci is currently the President-Lonzas Cell & Gene Division at MorphoSys AG. He started this position in 2022. Prior to his current role, he graduated from Humboldt-Universität zu Berlin. |
